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Abstract The neuraminidase inhibitor oseltamivir (Tamiflu®)
is currently the first-line therapy for patients with
influenza virus infection. Common analysis of the
prodrug and its active metabolite oseltamivircarboxylate
is determined via extraction from plasma. Compared with
these assays, dried blood spot (DBS) analysis provides
several advantages, including a minimum sample volume
required for the measurement of drugs in whole blood.
Samples can easily be obtained via a simple, non-
invasive finger or heel prick. Mainly, these characteristics
make DBS an ideal tool for pediatrics and to measure
multiple time points such as those needed in therapeutic
drug monitoring or pharmacokinetic studies. Additionally,
DBS sample preparation, stability, and storage are usually
most convenient. In the present work, we developed and fully
validated a DBS assay for the simultaneous determination of
oseltamivir and oseltamivircarboxylate concentrations in
human whole blood. We demonstrate the simplicity of DBS
sample preparation, and a fast, accurate and reproducible
analysis using ultra high-performance liquid chromatography
coupled to a triple quadrupole mass spectrometer. A thorough
validation on the basis of the most recent FDA guidelines for
bioanalytical method validation showed that the method is
selective, precise, and accurate (≤15% RSD), and sensitive
over the relevant clinical range of 5–1,500 ng/mL for
oseltamivir and 20–1,500 ng/mL for the oseltamivircar-
boxylate metabolite. As a proof of concept, oseltamivir and
oseltamivircarboxylate levels were determined in DBS
obtained from healthy volunteers who received a single oral
dose of Tamiflu®.
Keywords Ultra high-performance liquid chromatography
(UHPLC) .Mass spectrometry (MS) . Dried blood spot
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Introduction
The neuraminidase (NA) are a family of enzymes, which
cleave the sialic acid (derivative of neuraminic acids)
residue from cellular glycoproteins and lipids [1]. These
enzymes are essential for influenza viruses in order to
spread within the host. The process allows the virus to
detach from the host cell after replication and consequently
infects further host cells. Oseltamivircarboxylate (OSC), the
active metabolite of oseltamivir (OS) (Tamiflu®, Hoffmann-
La Roche, Nutley, NJ) provides a pharmacophore, which
resembles sialic acid and selectively inhibits the activity
of the enzyme, thus preventing the virus from spreading
in the host.
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Treatment of influenza virus infection is particularly
important for patients who are at risk for a complicated course
of influenza. These patient groups include neonates, infants,
young children, pregnant women, elderly, and immunocom-
promised patients [2–4]. Over the last couple of years,
Tamiflu® resistance has emerged in seasonal influenza A
(H1N1) viruses. However, it seems that this influenza strain
has been replaced by the pandemic influenza AH1N1/09 virus,
which is still sensitive to Tamiflu®. As with most of the drugs,
a precise dosing regime for infants and young children is based
on calculations according to their body weight and due to
empiric data on efficacy [5]. Determinations of a therapeutic
window in this patient subgroup are often hampered by an
inadequate blood/plasma sampling and sensitive analytical
methods. Dried blood spot (DBS) analysis provides an ideal
tool to monitor circulating drug levels and is also feasible to
obtain drug pharmacokinetics (PK studies) [6, 7]. From a
finger or heel prick minimum amounts of blood, usually 10–
30 μL are spotted directly on specifically designed filter
cards, which are subsequently extracted in an on- or off-line
procedure [8] to be further analyzed in a high-throughput
manner by gas chromatography–mass spectrometry (GC-MS)
[9] or ultra high-performance liquid chromatography
(UHPLC) coupled to ultra violet (UV), fluorescence, or mass
spectrometer (MS) detectors [10]. The use of MS detectors
applying multiple reaction monitoring (MRM) mode has the
advantage of being usually very sensitive and more selective
than other common LC detectors. Moreover, they provide the
possibility to monitor multiple analytes simultaneously and do
not depend on fluorescence or UV active chemical structures.
The current work describes a novel DBS UHPLC-MS/MS
method which allows to simultaneously monitor OS and OSC
concentrations in human whole blood samples. This work
expands on a just recently published DBS method for
measurement of OS and OSC in rodent blood [8]. Here, we
describe for the first time a method to measure OS and OSC
concentrations in human whole blood via DBS. The assay
was validated on the basis of the latest Food and Drug
Administration (FDA) guideline for bioanalytical method
validation [11], and was applied to a small set of samples
obtained from healthy subjects, as a proof of concept. The
assay requires minimum blood volumes, which can easily be
obtained by finger or heel prick, and it obviates plasma
centrifugation to simplify sample preparation. Previously
reported ester hydrolysis [12] was not observed on DBS
during method development and validation, also shown by
the various stability tests of OS and OSC on DBS cards.
Materials and methods
Chemicals and reagents All solvents were of ULC/MS
grade and were purchased from Biosolve (Valkenswaard,
the Netherlands). The standards for OS and OSC (see
Fig. 1) and their respective stable isotope-labeled internal
standards d3-OS and d3-OSC were kindly provided by the
Hoffmann-La Roche Ltd. (Basel, Switzerland). Filter paper
from Schleicher & Schuell 2992 (Schleicher & Schuell
BioScience GmbH, Dassel, Germany) was used for the
validation and the patient samples.
Sample preparation
For the preparation of the DBS during the validation, blank
whole blood (WB) was collected from two healthy donors
(Sanquin, Rotterdam, the Netherlands). Blood was sampled
in single-use evacuated fluoride/oxalate blood collection
tubes containing 10 mg sodium fluoride and 8 mg
potassium oxalate (BD VACUTAINER®) supplied by BD
(Franklin Lakes, NJ, USA). Aliquots were kept in the
freezer and were prepared freshly every day. Twenty
microliters of blood were spotted with an Eppendorf pipette
(Wesseling-Berzdorf, Germany) onto the DBS cards and
dried for a minimum of 2 h at room temperature (RT).
For the measurement of the clinical samples, WB was
collected by finger prick and spotted directly on DBS cards.
The blood from the arm vein was collected in fluoride/
oxalate tubes and spotted directly from the tubes onto the
DBS paper as described above.
After drying, 4 μL of a mixture of the two internal
standards (d-OS 50 ng/mL and d-OSC 250 ng/mL) were
spotted onto the DBS and the cards were dried for another
30 min at RT.
The extraction of the DBS was conducted by manually
punching out a disk (∼5 mm Ø) into an Eppendorf tube.
Extraction was achieved by the addition of 75 μL 5%
methanol (MeOH) in water, followed by 10 min sonication.
Forty-five microliters of the extract were transferred into a
fresh Eppendorf tube and combined with 30 μL of
acetonitrile (kept at −20 °C) for protein precipitation. The
mixture was centrifuged for 10 min (14.000 rpm, 4 °C), and
the supernatant was diluted 1:4 with water prior to analysis.
Chromatographic conditions
An Ascentis® Express C18 reversed-phase column (100×
2.1 mm, 2.7 μm) from Supelco (Munich, Germany) and an
Ascentis® Express guard column (C18, 2.1 mm I.D.) from
Supelco (Munich, Germany) were used for LC separations.
The chromatographic separation was carried out on an
Ultimate 3000 Rapid Separation LC system from Dionex
Benelux B.V. (Amsterdam, the Netherlands). Chromato-
graphic conditions were as follows: gradient elution was
performed with two solvents: solvent A, 0.1% formic acid
(FA) in water and solvent B, 0.1% FA in MeOH. The
program was initiated with a linear gradient from 25% to
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100% B at 0.25 min and kept constant for 2.75 min. At
3 min, the column was equilibrated again with 25% solvent
B for 3 min. Total run time was 6 min with a constant flow
rate of 350 μL/min and a constant column oven tempera-
ture of 30 °C. The retention time of OSC was 1.88 min and
for OS 3.20 min.
The systemwas coupled to an API 4000 QTRAP linear ion
trap mass spectrometer (AB Sciex, Concord, ON, Canada).
The mass spectrometer was run in positive MRM mode with
nitrogen as nebulizer, drying and collision gas. Following
parameters were used: curtain gas, 25 (arbitrary units);
collision gas pressure, medium; ion-spray voltage (IS),
5,000 V; temperature, 650 °C; nebulizer gas, 20 (arbitrary
units); declustering potential, 20 V; entrance potential, 10 V;
collision energy, 15 eV for d-OS, OS, and OSC and 30 eV for
d-OSC; collision cell exit potential, 10 V for all analytes,
except OSC, for which it was set at 20 eV. The MRM
transitions were (OS) m/z 313+→225, (d-OS) m/z 316+→
228, (OSC) m/z 285+→138, and (d-OSC) m/z 288+→200,
respectively (see also Fig. 1). Selection of each MRM
transition was based on optimal intensities obtained for the
fragment ion during method development (data not shown).
Post-column infusion experiments
A mixture of the two analytes OS (50 ng/mL) and OSC
(200 ng/mL) was prepared in water and the solution was
directly infused from a syringe pump (Harvard Instruments,
Holliston, MA) into the ESI source via a T-piece, where the
mobile phase was introduced from the UHPLC system at
assay flow rate, column and gradient conditions. Once a
steady selected ion current (XIC) for the MRM transitions
of OS and OSC was achieved, 60 μL extract from blank
blood spot sample were injected onto the column (Fig. 2).
Method validation
Validation samples For the validation samples, fresh WB
was collected in BD Vacutainer® fluoride/oxalate tubes
from two healthy donors and aliquots were stored at −20 °C.
Blank blood samples (spiked with 3 μL of water instead of
analyte solution) did not show any interfering signals under
assay conditions. Furthermore, quality control (QC) samples
prepared (see text below) in blood of donor 1 were calculated
with a calibration curve of standards prepared in blood from
donor 2, and vice versa to demonstrate the independency of
the assay results from sample matrix.
Stock solutions and dilutions thereof were prepared in
water for all analytes. Calibration standards were prepared
daily by adding 3 μL of the respective OS–OSC mixture to
27 μL of blood to obtain one sample. Calibration standards
were chosen at the following concentrations for OS: 5, 10,
20, 30, 50, 100, 250, 500, 1,000, and 1,500 ng/mL and for
OSC: 20, 30, 50, 100, 250, 500, 1,000, and 1,500 ng/mL.
Calibration curves included a blank sample and two zero
samples, spiked with each internal standard separately.
QC samples were prepared in the following concentra-
tions (OS/OSC): 0/750, 75/200, and 150/75 ng/mL and
measured with n=4 for each QC sample.
Validation protocol The method validation was performed
in respect to the latest FDA guideline for method validation
of bioanalytical assays [11].
The selectivity of the method was determined by the
comparison of blood blank and two zero samples from two
donors, respectively. Linearity of the DBS assay was
verified by five calibration curves measured on five
separate days. Each one consisted of ten nonzero calibration
standards for OS and eight for OSC, covering the
concentration range from 5–1,500 ng/mL for OS and
20–1,500 ng/mL for OSC measured in the identical
calibration standards. The calibration curves were calculated
by linear regression using weighting for both analytes. The
back-calculated values are required to be within 15% relative
standard deviation (RSD) and 20% RSD at the lower limit of
quantification (LLOQ), from the nominal concentration. The
acceptance criteria for the correlation coefficients (r2) of the
calculated regression curves were 0.99 or higher.
OSC (active metabolite)
esterase activity
+ H2O
- EtOH
OS (prodrug)
(m/z 228)
m/z 225
(m/z 200)
m/z 138
Fig. 1 Enzymatic activation of the prodrug oseltamivir (OS) to
oseltamivircarboxylate (OSC). The dotted lines represent the frag-
mentation of the compounds during MRM measurements, including
the m/z value of the selected fragment ions of the analytes and the
respective stable isotope internal standards (values in brackets). For
the stable isotope-labeled internal standards, the methyl group of the
amid function is replaced by –CD3 group, respectively
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The determination of the LLOQ was conducted by
spiking six WB samples with OS and OSC at the lower end
of the calibration curves (5 and 20 ng/mL, respectively).
Results were recalculated with a freshly prepared calibration
curve.
Intra- and interday accuracy and precision were deter-
mined by analyzing three times four replicates of each QC
sample together with a freshly prepared calibration curve in
one analytical run within 1 day (intraday) and by analyzing
three times four replicates of each QC sample together with
a freshly prepared calibration curve in one analytical run on
three consecutive days (interday). The mean, the standard
deviation, the RSD, and bias were calculated.
The recovery of the method was determined by spiking
three WB samples with OS and OSC (75 and 200 ng/mL,
respectively), spotting and cutting out the whole blood spot.
As a comparison, three blank blood spots, completely
extracted and spiked in the extraction solvent with the same
concentration were used. Samples were measured and
results calculated by setting the samples spiked after
extraction as 100%.
Stability of OS and OSC was determined for all QC
samples with n=4, for 0, 1, 3, and 7 days at RT and in the
fridge at 4 °C; at −20 and +40 °C for 24 h. All samples
were kept in air-tight plastic containers for time of storage.
Additionally, 12 h autosampler stability was tested for the
extracted solution.
Clinical samples
As a proof of concept study, three healthy volunteers (three
male adults) took a single Tamiflu® capsule (75 mg), after
signing written informed consent. Blood obtained via finger
prick and from the median cubital vein was collected 2.5
(±15 min) and 4.25 h (±15 min) after administration of the
capsule by trained personnel.
Results and discussion
The method described in the current work shows the
development of a Tamiflu® DBS assay in combination
with a fast, accurate, precise, and reproducible UHPLC-
MS/MS application. The assay was validated based on
criteria described by the most recent FDA guideline for
bioanalytical method validation [11]. The feasibility of
the analytical procedure was demonstrated in a clinical
proof of concept study. To the best of the author’s
knowledge, this study is the first report in the field of
DBS analysis which assesses the effect of the type of
whole blood, i.e., venous WB in blood collection tubes
containing additives or capillary WB obtained by finger
prick, on the measured concentrations of OS and OSC.
This comparison demonstrated that results obtained with
the newly developed assay were not influenced by
additives (fluoride/oxalate) in the blood collection tubes.
Fluoride/oxalate tubes are the tubes of choice for OS
blood sampling [13]. Further proof of the accurate and
reproducible analytical method was obtained via post-
column infusion chromatograms, demonstrating no inter-
ference (ion suppression or enhancement) at the respective
retention times of the analytes (see Fig. 2), despite an
extraction protocol for the DBS using 5% methanol in
water. Watery extraction solvents are technically more
prone to show matrix effects, as endogenous, hydrophilic
compounds get easily extracted together with the drug of
interest [14]. This interference can mainly be observed in
the infusion chromatogram (see Fig. 2) during the first
minute.
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Fig. 2 Post-column infusion
chromatograms. Indicated by
the arrows are the retention
times of OSC tR1=1.88 min and
OS tR2=3.20 min. The major
drops in the XIC signal (for OS
m/z 313+→225 and OSC m/z
285+→138) are due to ion
suppression of eluting matrix
compounds at the beginning of
the gradient and due to a sudden
change in solvent composition
after ∼3.4 min
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Method validation
Selectivity No interfering signals were observed at the
respective retention times of t=1.88 min (OSC) and t=
3.20 min (OS) when blank or zero sample (spiked with IS)
blood spots were analyzed.
Linearity Five measurements of the calibration standards,
freshly prepared on five separate days, showed good linearity
over the entire calibration range from 5–1,500 ng/mL for OS
and 20–1,500 ng/mL for OSC. To obtain the best fit of the
calibration standards a weighting factor of 1/x2 was used for
each analyte. This factor was determined through a
comparison of the calculated correlation coefficients
(r2 values) and the sums of the absolute values of the relative
errors for the calibration curves when different weighting
factors were applied in the calculation (data not shown). The
r2 values were consistently greater than 0.991, with a mean
of 0.9938 for OS and 0.9987 for OSC, respectively. The
RSD values of the calculated standard concentrations from
their nominal values were constantly ≤15% for all values,
including the respective LLOQs. These results were well in
line with the FDA specifications [11].
Lower limit of quantification The lower limit of quantifi-
cation, determined in six spiked DBS samples was 5 ng/mL
for OS and 20 ng/mL for OSC. Measurements for OS
showed an average of 5.7 ng/mL±3.3% (bias=5.1%) and
for OSC an average of 21.3 ng/mL±8.5% (bias=6.7%).
These values are well below the general FDA acceptance
criterion of 20% RSD for the LLOQ [11]. A representative
chromatogram at the LLOQ is shown in Fig. 3.
Accuracy and precision Accuracy and precision were deter-
mined for three independent measurements within 1 day and
on three consecutive days. Results can be found in Table 1,
which demonstrates that the acceptance criteria of a
maximum RSD of 15% are fulfilled for all QC samples.
Recovery The relative recoveries for OS (75 ng/mL) and
OSC (200 ng/mL) were determined with 92.8% and
100.2%, respectively. These results demonstrate that there
was almost no sample loss during sample preparation.
Stability All stability tests showed sufficient stability of
both analytes, OS and OSC under various test conditions.
As shown in Table 2, on card stability of both analytes
showed no significant sample loss over 7 days at RT and at
4 °C, simulating collection, shipment, and storage condi-
tion. Values for 1 and 3 days stability were well below
15% accuracy (bias) and precision (data not shown).
Moreover, stability could be demonstrated for 24 h at −20
and +40 °C, simulating shipment conditions. Autosampler
stability was shown for the extracted QC samples at 4 °C
in the dark to guarantee stability during higher sample
throughput.
No significant sample loss was shown under any of the
test conditions.
Analysis of clinical samples
Three healthy volunteers were treated once daily with
75 mg Tamiflu® and blood samples were collected at
two different time points, ∼2.5 and 4.25 h after oral
administration. These time points were chosen in a time
window in which the tmax of the prodrug OS and the
active metabolite OSC were expected, as previously
described [15]. Concentrations were determined in DBS
obtained from finger pricks (capillary WB) and in DBS
OSC OS
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Fig. 3 Exemplified chromato-
gram of OS (Rt=3.20 min)
and OSC (Rt=1.88 min) at the
LLOQ, monitored with
scheduled MRMs for the
following mass transitions
OS m/z 313+→225 and
OSC m/z 285+→138
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from in BD Vacutainer® fluoride/oxalate tubes collected
blood (venous WB). These tubes were also used for the
collection of the blank blood used during the validation.
Results are shown in Table 3. The values are well within
the plasma concentrations described in literature [16]. The
listed delta values describe the relative difference between
the values obtained from the finger pricks and via the
blood collected in fluoride/oxalate blood collection tubes
from the cubital veins, prior spotting on DBS paper. The
OS/OSC levels were comparable in DBS and venous WB,
as judged by the delta values.
Conclusions
The current work describe for the first time a complete
method validation for the simultaneous measurement of OS
and OSC in WB using DBS. In the fast growing field of
pharmaceutical DBS analysis, we demonstrated with the
current work that DBS are feasible for Tamiflu® concen-
tration measurements in humans. The importance of this
novel approach lies in the greatly facilitated approach for
blood collection, especially in neonates, infants, and small
children (finger or heel prick), where collection of larger
Table 1 Intra- and interday accuracy and precision
Nominal
concentrations
(ng/mL)
Mean calculated
concentrations
(ng/mL)
Accuracy
(bias %)
Precision
(% CV)
OS
Intraday
(n=3)
75 70.6 −5.9 4.7
150 159.6 6.4 1.8
Interday
(n=3)
75 72.2 −3.7 6.5
150 151.0 0.7 8.7
OSC
Intraday
(n=3)
75 78.5 4.6 4.5
200 219.3 9.7 1.0
750 686.3 −8.5 1.4
Interday
(n=3)
75 74.7 −0.5 7.3
200 221.1 10.5 0.8
750 708.5 −5.5 4.4
Intra- and interday accuracy and precision measurements of three
independent measurements of the respective QC samples for OS and
OSC, n=4. The accuracy is expressed as the bias of the measurement
and the precision as % CV
Condition Nominal concentrations (ng/mL) Accuracy (bias %) Precision (% CV)
OS OSC OS OSC OS OSC
RT at day 7 75 4.9 6.0
75 200 −11.2 3.8 3.8 3.1
150 750 −8.9 −3.6 6.8 4.7
4 °C at day 7 75 0.9 6.7
75 200 −6.8 1.4 8.3 4.3
150 750 −9.8 −12.2 4.1 1.7
24 h at −20 °C 75 −0.1 5.5
75 200 −10.6 −5.0 5.5 8.9
150 750 −7.9 −7.6 10.0 4.0
24 h at +40 °C 75 1.5 3.4
75 200 −13.1 0.7 7.2 7.7
150 750 −8.6 −5.4 5.6 6.1
Autosampler at 4 °C (dark) 75 4.1 3.7
75 200 −7.8 10.8 7.6 1.6
150 750 8.7 −9.3 3.4 4.5
Table 2 Stability of DBS and
extracts
Results of various stability test
conditions. Stability at room
temperature (RT) and in the
fridge at 4 °C was performed on
day 0 and after 1, 3, and 7 days.
Exemplified results are shown
for day 7. Other values for
days 1 and 3 were well within
the acceptance criteria (data not
shown). Furthermore, on card
stability was tested for 24 h
at −20 and +40 °C. The stability
of the liquid DBS extract was
tested for 12 h at 4 °C in the
autosampler. The accuracy is
expressed as the bias of the
measurement and the precision
as % CV
Table 3 Blood concentrations obtained from healthy volunteers
Donor
no.
t (h) OS concentrations
(ng/mL)
OSC concentartions
(ng/mL)
Finger
prick
Arm
vein
Δ
(%)
Finger
prick
Arm
vein
Δ
(%)
1 2.5 27 25 6.4 125 149 −19.0
2 27 25 7.2 148 143 3.1
3 31 29 5.8 90 83 7.9
1 4.25 n.d. n.d. – 242 189 22.0
2 n.d. n.d. – 175 151 14.0
3 5 6 −19.9 140 129 7.5
Blood concentrations from healthy volunteers were measured using
blood from the finger prick compared with blood taken from the
cubital vein via blood collection tubes. All blood samples were
spotted on DBS cards. Volunteers took one tablet of Tamiflu® at time
point t=0, and samples were taken at t=2.5 and t=4.25. The delta
and the cubital vein, expressed as percentage of the finger prick value
n.d. not determined, as values were below the LLOQ
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values (Δ) show the difference between the value of the finger prick
blood volumes may be problematic. The work described
herein will also open possibilities for therapeutic drug
monitoring (TDM), as again only small sample volumes
(20 μL/spot) are needed and a more invasive venous
puncture can be avoided.
Furthermore, OS potentially undergoes further ester
hydrolysis (esterase activity) in collected WB samples
[12] and could therefore influence accurate determinations
of plasma OS and OSC (OSC is the hydrolysis product of
OS) concentrations. A recently published, elaborate study
by Heinig et al. of Tamiflu DBS analysis in rat blood
specifically investigated stability of OS during drying time
of different DBS cards and found treated (DMPK-A and
DMPK-B) in contrast to chemically untreated cards to
stabilize the drug [8]. This stands in contrast to a report by
D’Arienzo et al. who could not observe ester hydrolysis on
untreated cards (Whatman 903 Protein Saver) [17]. In order
to investigate this stability issue, we compared DBS spotted
from fluoride/oxalate tubes to directly spotted blood from
the finger prick. The fluoride/oxalate blood collection tubes
were shown to be necessary to prevent ester hydrolysis of
OS after blood sampling [13, 18]. The small pilot study
presented in the current work did not show any significant
differences in OS or OSC concentrations in DBS collected
via these two ways. Furthermore, we did not observe any
significant degradation during method development or in a
separate calibration curve for OS. However, since these
calibration samples were prepared in previously frozen
blood a loss of esterase activity during as a consequence of
freeze–thaw cycles cannot be ruled out. Further research
comparing a validated plasma assay and the validated DBS
assay, described in the current work will be necessary to
specifically address this issue in a larger patient collective.
In the future, studies will also be performed to determine
ideal dosing regimes in infants and small children [19],
where dosing is currently calculated according to the
bodyweight or according to empiric amounts, but not based
on actual blood levels in influenza-infected children.
Besides pediatrics, this assay will also provide the
possibility for future PK and TDM studies in clinical and
nonclinical environments.
Taken together, further research in the context of DBS
analysis of Tamiflu® will have to address more technical
issues like, e.g., the influence of different hematocrit
(Ht) values, paper quality, sampling instructions, etc. [14].
These investigations will also depend on the study of
interest and the setting of the sample collection.
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